Abstract: Thirty patients with Schamberg's disease were started on pentoxifylline (400 mg three times
daily) for a period of 9 weeks. Improvement was assessed at 3 weekly intervals by two
observers independently and graded as mild (<25%), moderate (25-50%) and marked
(>50%). Marked improvement was observed in 15/30 (50%) patients. We conclude that
pentoxifylline should be considered as first line therapy in all patients with Schamberg's
disease
